Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

No abstract is available for this paper.

• Publication year

  1975

• Venue

  Journal of Neurology

• Publication date

  1975-12-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/BF00312459PMID 56427
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Parkinson's disease and striatal dopamine: In vivo morphological evidence for the presence of dopamine in the human brain

  2005cited by this paper
• Treatment of Parkinson's disease with l-DOPA and decarboxylase inhibitor

  2004cited by this paper
• La barrière capillaire pour la dopa dans le cerveau et les différents organes

  2004cited by this paper
• ABNORMAL INVOLUNTARY MOVEMENTS IN RELATION TO ANTICHOLINERGICS AND LEVODOPA THERAPY

  1975cited by this paper
• ABNORMAL INVOLUNTARY MOVEMENTS INDUCED BY ANTICHOLINERGIC THERAPY

  1974cited by this paper
• Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia

  1974cited by this paper
• APPRAISAL OF LONG‐TERM LEVODOPA TREATMENT OF PARKINSONISM WITH SPECIAL REFERENCE TO THERAPY LIMITING FACTORS

  1974cited by this paper
• [Dyskinesia induced by anticholinergic drugs--electrophysiological analysis].

  1974cited by this paper
• Antiparkinson drugs as causal agents in tardive dyskinesia.

  1973cited by this paper
• Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.

  1973cited by this paper
• ANTIPARKINSON DRUGS AS CAUSAL AGENTS IN TARDIVE DYSKINESIA

  1973cited by this paper
• Modification of levodopa effect by systemic decarboxylase inhibition.

  1973cited by this paper
• [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].

  1973cited by this paper
• Plasma concentration of levodopa in patients with Parkinson's disease.

  1973cited by this paper
• Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).

  1972cited by this paper
• Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).

  1972cited by this paper
• THE RISE TIME OF INTRACRANIAL ECHO PULSATIONS AND INTRACRANIAL PRESSURE

  1972cited by this paper
• [L-Dopa therapy in Parkinson's disease. A double-blind study].

  1971cited by this paper
• Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation

  1971cited by this paper
• [Levodopa and Parkinsonism. A double-blind study].

  1971cited by this paper
• [Treatment of Parkinson's disease with L-dopa].

  1970cited by this paper
• Treatment of parkinsonism with levodopa.

  1969cited by this paper
• [The capillary barrier for dopa in brain and different organs].

  1969cited by this paper
• L-dopa in idiopathic parkinsonism.

  1969cited by this paper
• Critical analysis of the disability in Parkinson's disease.

  1968cited by this paper
• A Double Blind Study of l-Dopa Treatment in Parkinson's Disease

  1968cited by this paper
• Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.

  1968cited by this paper
• A double blind study of 1-dopa treatment in Parkinson's disease.

  1968cited by this paper
• Critical analysis of the disability in Parkinson's disease.

  1968cited by this paper
• Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase

  1967cited by this paper

• Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutation.

  2025cites this paper
• Selective loss of Scn2a in ventral tegmental area dopaminergic neurons leads to dopamine system hypofunction and autistic-like behaviors.

  2025cites this paper
• Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson’s Disease

  2024cites this paper
• Evidence for dopaminergic involvement in endogenous modulation of pain relief

  2023cites this paper
• Application of net analyte signal and principal component regression for rapid simultaneous determination of Levodopa and carbidopa in commercial pharmaceutical formulation and breast (human) milk sample using spectrophotometric method.

  2022cites this paper
• Cystathionine-β-synthase: Molecular Regulation and Pharmacological Inhibition

  2020cites this paper
• Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey

  2018cites this paper
• Improving l‐dopa therapy: The development of enzyme inhibitors

  2015influential citation
• Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study.

  2011cites this paper
• PARKINSON ’ S DISEASE

  2010cites this paper
• Current status of symptomatic medical therapy in Parkinson’s disease

  2008cites this paper
• The effects of entacapone on cardiorespiratory, autonomic, and clinical responses in L-dopa-treated patients with Parkinson's disease

  2006cites this paper
• Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.

  2003cites this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cites this paper
• Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.

  1979cites this paper
• Levodopa with benserazide or carbidopa in Parkinson disease

  1979cites this paper
• Dopaminergic agonist Ro 8–4650 in Parkinson's disease

  1978cites this paper
• Long‐term treatment of Parkinson's disease with L‐Dopa and Dopa‐decarboxylase inhibitor: Therapeutic results and side effects

  1978cites this paper
• ACTIONS OF TETRAHYDROPAPAVEROLINE ON THE CARDIOVASCULAR SYSTEM AND SKELETAL MUSCLES OF THE ANAESTHETIZED CAT AND ON GUINEA‐PIG SOLEUS MUSCLE IN VITRO

  1978cites this paper
• Recent advances in research on Parkinsonism.

  1978cites this paper
• [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].

  1977cites this paper
• Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.

  1976cites this paper